Core Insights - Bavarian Nordic A/S has expanded its strategic partnership with Serum Institute of India Pvt. Ltd. to include a contract manufacturing agreement for the chikungunya vaccine, allowing for a full tech transfer of the manufacturing process to scale capacity for future supply to low- and middle-income countries [1][8] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, with a strong portfolio in mpox and smallpox vaccines, as well as travel vaccines [6] - Serum Institute of India is the world's largest vaccine manufacturer, producing vaccines for various diseases and operating with an annual capacity of 4 billion doses [7] Vaccine Details - The chikungunya vaccine (CHIKV VLP) is a single-dose, prefilled, adjuvanted recombinant protein vaccine designed for individuals aged 12 and older, with protective immunity developing as early as one week post-vaccination [3] - The vaccine is non-infectious, containing no viral genetic material, making it safe for a broad range of individuals [4] Disease Context - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, causing significant outbreaks, particularly in Brazil, which reported nearly 500,000 cases and over 200 deaths in 2025 [5]